Peptides for women: what the trials in women show, and after 40
Reviewed 16 sourcesPublished by PepVault
Which peptides were tested in women: semaglutide, tirzepatide, PT-141, GHK-Cu, collagen, BPC-157, tesamorelin and HGH, with how many women and what was found.

- Last reviewed
- Sources
- 16
- Questions
- 8
- Compounds
- 8
The short answer
The peptides with solid data in women are the GLP-1s and bremelanotide. Women were 68 to 74% of the main semaglutide and tirzepatide trials, and where results were split by sex, women lost more weight than men. Vyleesi is approved only for premenopausal women. GHK-Cu and collagen have small skin trials in women, BPC-157 one 12-woman pilot, and tesamorelin and HGH were studied mostly in men.
Evidence: Large randomized trials for semaglutide and tirzepatide (mostly women) and for bremelanotide (women only); for GHK-Cu, collagen and HGH, small randomized trials; for BPC-157, one uncontrolled pilot; tesamorelin's trials were mostly men.

Which peptides have actually been tested in women?
Most lists of "peptides for women" name a dozen compounds and give no trial numbers. The table below does the opposite: for each compound women search, it shows what was studied, how many women were in the human studies, what was found, and how strong that evidence is. The labels and papers are current as of November 2026.
| Compound | What was studied | Women in the human studies | What was found | Evidence level |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Weight, 68 weeks (STEP 1) and 4 years (SELECT) | 74% of 1,961 adults in STEP 11; 27.7% of 17,604 in SELECT3 | In SELECT at 2 years, women lost 11.1% more than placebo, men 7.5%3 | Approved drug, large randomized trials |
| Tirzepatide (Zepbound) | Weight, 72 weeks (SURMOUNT-1) | 68% of 2,539 adults2 | In a Mayo Clinic cohort of 1,039 (57% women), women lost 15.1% at 15 months, men 10.7%4 | Approved drug, large randomized trials; the sex split comes from an observational clinic cohort |
| Bremelanotide (Vyleesi, PT-141) | Low sexual desire with distress, 24 weeks | 1,267 premenopausal women, mean age 396 | Desire score rose 0.35 points more than on placebo; nausea in 40%65 | Approved for premenopausal women only |
| GHK-Cu (on the skin) | Facial wrinkles, 8 weeks | 40 women aged 40 to 65, 39 finished7 | Wrinkle volume fell 55.8% more than on a serum base without GHK-Cu7 | One small randomized trial |
| Collagen peptides (by mouth) | Skin aging; bone density | 19 skin trials, 1,125 people, 95% women8; 131 postmenopausal women9 | Better hydration, elasticity and wrinkles8; spine and hip bone density rose against placebo9 | Several small randomized trials; one bone trial |
| BPC-157 | Bladder pain (interstitial cystitis) | 12 women aged 39 to 7610 | 10 of 12 reported full relief after one treatment; no placebo group10 | One uncontrolled pilot |
| Tesamorelin (Egrifta) | Belly fat in people with HIV, 26 weeks | 14 to 16% of 816 adults in two trials12 | Visceral fat fell 15.4% against placebo, men and women pooled13 | Approved drug for HIV; few women |
| HGH (somatropin) | Body composition in healthy older adults, 26 weeks | 57 women (and 74 men) aged 65 to 8814 | Lean mass +1.0 kg against +0.4 kg on placebo; strength did not change14 | One randomized trial that reports older women separately |
The pattern is plain. The two GLP-1s were tested in thousands of women, and Vyleesi was tested only in women. Everything else rests on a few dozen women each, or on trials that were mostly men.

Do women lose more weight on semaglutide and tirzepatide?
In the analyses that split results by sex, yes. In SELECT, a four-year semaglutide trial of 17,604 adults with heart disease, women had lost 11.1% more weight than women on placebo at two years, and men 7.5% more than men on placebo3. In 1,039 Mayo Clinic patients who stayed on tirzepatide for at least a year, women lost 15.1% of their weight at 15 months and men 10.7%; female sex predicted more loss, and age did not once the other factors were counted4. That second study is an observational cohort drawn from clinic records, not a randomized trial. Both labels state that weight fell irrespective of sex12.
One side effect also splits by sex. On Wegovy 2.4 mg, 4% of women and 0.9% of men reported hair loss (2% of women on placebo), and 8.4% of women on the newer 7.2 mg dose; on Zepbound, 7.1% of women and 0.5% of men (1.3% of women on placebo)12. Both labels tie it to the weight loss, and on Zepbound no one stopped treatment because of it2. It is usually a temporary shed (the hair-loss guide covers why).
Commonly reported: women on a GLP-1 describe extra shedding in the brush or shower that starts a few months in and settles later, and an appetite that changes across the menstrual cycle in the first months.
- A weekly weigh-in shows your own curve against the trial numbers, which are averages at 68 to 72 weeks.
- A photo in the same light every month shows hair changes more fairly than memory.
PepVault keeps the weight log and the dose log side by side, with a reminder on dose day, so each step-up and its weight trend sit in one record. Track your weight in PepVault
What is PT-141 approved for in women?
Bremelanotide, sold as Vyleesi, is approved for premenopausal women with acquired, generalized low sexual desire that causes marked distress, and is not approved for postmenopausal women or men5. In the two RECONNECT trials, 1,267 women were randomized, and desire rose 0.35 points more than on placebo on a scale that runs from 1.2 to 665. Nausea was the most common effect, in 40% against 1.3% on placebo, and it improved for most women by the second dose5. The PT-141 guide covers the trials in detail.
Do GHK-Cu and collagen work on women's skin?
Both have small human trials, and the trials were mostly women. GHK-Cu is a copper-carrying peptide of three amino acids. In a double-blind split-face trial, 40 women aged 40 to 65 applied a GHK-Cu serum to one side of the face twice a day for 8 weeks, and either the serum base without GHK-Cu or a Matrixyl 3000 product to the other side; 39 finished. With about 20 women in each comparison, wrinkle volume fell 55.8% more on the GHK-Cu side than on the base, and 31.6% more than on Matrixyl 3000. The serum's maker funded the trial7.
Collagen peptides are food protein cut into fragments and taken by mouth. A 2021 meta-analysis pooled 19 randomized trials with 1,125 people aged 20 to 70, 95% of them women, and found better skin hydration, elasticity and wrinkles than on placebo after about 90 days8.
Is there any BPC-157 data in women?
One small study, and it is all women. Twelve women aged 39 to 76 with interstitial cystitis, a long-term bladder pain condition, who had not responded to the approved drug, had BPC-157 injected around the inflamed area of the bladder in a single procedure. Ten of the 12 reported full relief and the other two 80%, and no side effects were reported10. There was no placebo group. The other human reports are a review of 16 knee-pain patients' clinic charts, which gives no result by sex in its abstract11, and a two-person intravenous safety pilot that included one woman, aged 68, with no side effects reported16. No human study compares BPC-157 in women and men.
Were women in the tesamorelin and HGH trials?
Few. Tesamorelin, a lab-made copy of the hormone that tells the pituitary to release growth hormone (GHRH), was tested in the two trials on its label, of 412 and 404 adults with HIV and excess belly fat, and 86% and 84% of them were men12. Pooled, it cut visceral fat, the fat around the organs, 15.4% more than placebo over 26 weeks13. A PubMed search found no published tesamorelin trial in women alone.
HGH has one well-known randomized trial that reports older women on their own. In its 57 healthy women aged 65 to 88 (the trial also enrolled 74 men), 26 weeks of growth hormone raised lean mass by 1.0 kg against 0.4 kg on placebo, and by 2.1 kg when combined with hormone therapy. Fat mass fell, but strength and fitness did not change significantly, and 39% of women on growth hormone had swelling against none on placebo14. The Genotropin label adds that women with normal estrogen levels may need higher doses than men to reach the same treatment goal, and that oral estrogen can raise the dose a woman needs15.
Which peptides have data after 40 and after menopause?
Several of the trials above are trials of women past 40. The GHK-Cu trial enrolled women aged 40 to 657, the BPC-157 pilot women with a mean age of 5810, and the HGH trial women aged 65 to 8814. For menopause itself, the GLP-1s have the most data: the GLP-1s and menopause guide covers weight loss before, during and after menopause, hormone therapy and bone.
For bone, the clearest peptide trial is collagen. In 131 postmenopausal women with low bone density, mean age 64, a trial's 5 g of specific collagen peptides a day for 12 months raised the spine T-score by 0.1 while it fell 0.03 on placebo, and the hip (femoral neck) T-score by 0.09 against a fall of 0.01; 102 women finished, and all 131 were counted9. A T-score compares bone density with a healthy young adult's. The changes are small, from one trial.
For muscle, the HGH trial is the caution: lean mass rose, strength did not14. Vyleesi does not extend past menopause, since its label excludes postmenopausal women5.
What do the labels say about pregnancy and the pill?
Each approved peptide's label speaks to pregnancy directly. Here is what each says, in the labels' terms.
- Wegovy: stop at least 2 months before a planned pregnancy, because semaglutide stays in the body a long time, and stop when pregnancy is recognized1.
- Zepbound: it may make birth-control pills less effective, because it slows how fast the stomach empties. Women on the pill switch to a non-pill method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase; non-oral hormonal methods should not be affected. Stop when pregnancy is recognized2.
- Vyleesi: use effective contraception while taking it, and stop if pregnancy is suspected5.
- Egrifta WR: not to be used in pregnancy; stop it if pregnancy occurs12.
Research peptides such as BPC-157 and GHK-Cu by injection have no pregnancy data at all. The GLP-1s and pregnancy guide covers the semaglutide and tirzepatide labels in full. When to stop before a planned pregnancy is your prescriber's call. If you find you are pregnant while taking one of these, stop as its label says and let them know that week.
Sources
- Novo Nordisk. WEGOVY (semaglutide) prescribing information, revised June 2026. DailyMed, SPL version 19. dailymed.nlm.nih.gov
- Eli Lilly. ZEPBOUND (tirzepatide) prescribing information, August 2026. DailyMed, SPL version 40. dailymed.nlm.nih.gov
- Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024. PubMed 38740993
- Castaneda R et al. Sex, not age, predicts weight loss outcomes with tirzepatide: a retrospective analysis. Obesity (Silver Spring). 2026. PubMed 42290037
- Cosette Pharmaceuticals. VYLEESI (bremelanotide) prescribing information. DailyMed, SPL version 2, November 2026. dailymed.nlm.nih.gov
- Kingsberg SA et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019. PubMed 31599840
- Badenhorst T, Svirskis D, Merrilees M et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci. 2016;4:166. doi.org
- de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol. 2021. PubMed 33742704
- König D et al. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women: a randomized controlled study. Nutrients. 2018. PubMed 29337906
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- Theratechnologies. EGRIFTA WR (tesamorelin) prescribing information. DailyMed, SPL version 2, July 2026. dailymed.nlm.nih.gov
- Falutz J et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
- Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002. PubMed 12425705
- Pfizer. GENOTROPIN (somatropin) prescribing information. DailyMed, SPL version 37, August 2026. dailymed.nlm.nih.gov
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.